Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
May 23, 2017 SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of up to ...
May 8, 2017 -- Presented additional Phase 3 EPIC and CARE trial data highlighting the safety and efficacy of plazomicin during late-breaker session at ECCMID -- -- Plazomicin registration activities on track; NDA submission planned for the second half of 2017 -- -- Co...
May 5, 2017 The Bill & Melinda Gates Foundation is committing up to $20 million in grant funding and equity investment to further the development of an antibody platform and discovery of monoclonal antibody candidates against gram-negative bacteria, including those that cause neonatal sepsis Importa...
May 1, 2017 SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its first quarter 2017 financial results on Mo...
Apr 24, 2017 -- Evaluation of EPIC Phase 3 data demonstrates sustained clinical cure with plazomicin compared to higher clinical relapse rate with meropenem -- -- 28-Day mortality benefit of plazomicin versus colistin in CARE Phase 3 trial in the bloodstream infection population was pronounced and wa...
Apr 13, 2017 -- Late-breaking oral presentations to highlight data from plazomicin Phase 3 EPIC and CARE clinical trials -- -- Newly-released in vitro data demonstrates activity of plazomicin against a large collection of colistin-resistant Enterobacteriaceae, including strains carrying the ...
Mar 30, 2017 SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at Needham & Company's 16th Annual Hea...
Mar 29, 2017 -- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company's late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those caused by CRE -- SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- ...
Mar 14, 2017 Achieved positive results in Phase 3 EPIC and CARE clinical trials of plazomicin; NDA submission planned for the second half of 2017 Unveiled new orally-administered antibacterial clinical candidate, C-Scape, to be evaluated in complicated urinary tract infections (cUTI) ...
Mar 6, 2017 SOUTH SAN FRANCISCO, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter 2016 financial results on Tues...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase